Kyle oversees financial operations for Bionatus as well as supporting business development activities across the portfolio. He is an accomplished executive with experience navigating established, high-growth business operations as well as startups. From 2005 until 2011, Kyle was the Director of Investor Relations and Corporate Development at Martek Biosciences (formerly NASDAQ: MATK), a leader in the innovation and production of high-value nutritional products from microalgae. At Martek, Kyle reported directly to two Martek EVPs and, in addition to day-to-day investor relations responsibility, played an integral role in the company’s expansion into new markets for which revenue grew from under $5 million to $60 million in five years. Kyle was involved in the negotiation and execution of numerous technology licensing and supply agreements with leading consumer packaged goods companies, as well as the related launch of the company’s flagship product, life’s DHA™, a branded functional ingredient. He also oversaw the company’s successful sustainability and USDA organic certification efforts. Martek was acquired by Royal DSM N.V. in 2011 for $1.1 billion.

Prior to joining Martek, Kyle was engaged in the financial sector for over six years, including being an Equity Research Analyst with Wm Smith & Company, a special situations equity research boutique based in Denver, CO, and prior to that, as an Analyst at SG Cowen Securities Corporation, a global investment bank focused on the technology and healthcare sectors. During his tenure at SG Cowen in Boston and New York, Mr. Stults was part of the mergers and acquisitions (M&A) advisory team and was directly involved in the completion of numerous public and private transactions ranging in size from $25 million to $1 billion.

Mr. Stults is a native of Wray, Colorado, and a graduate of the University of Denver’s Daniels College of Business where he graduated cum laude with a B.S. in Business Administration with an emphasis in Finance.